Ikonisys

Hospitex to Obtain International Patent for the BLOCKfast Cyto-Inclusion Kit

Regulatory News:

Ikonisys SA (Euronext Growth Paris: ALIKO), a company specializing in the early and accurate detection of cancers through a unique, fully automated solution for medical analysis laboratories, today announces that Hospitex International has obtained the international patent for the BLOCKfast cytoinclusion kit.

BLOCKfast facilitates the treatment of cells collected in the liquid phase and processes them in histology in a more innovative, efficient, and straightforward manner than traditional methods. Since its launch immediately after the application filing, the product has swiftly become a flagship offering in Hospitex's portfolio within the Italian market, finding utility in any pathological anatomy laboratory.

Recent commercial validations now present significant global commercial development prospects.

Produced entirely at the Florence plant, BLOCKfast is manufactured using sophisticated chemical processes and stringent quality control procedures, ensuring formal and substantive protection of the formula.

The patent, previously labeled "Patent Pending", has garnered international recognition, enabling broader access and enhanced dissemination of innovative Cancer Diagnosis solutions.

This achievement marks a significant stride in the company's mission to provide top-tier diagnostic solutions to cancer patients worldwide. It stands as a pivotal point in a broader R&D landscape, which anticipates numerous patents in the years ahead.

About Hospitex International

Hospitex International is the world leading company for cytology standardized monolayer preparations. With CYTOfast it has re-invented the cytological diagnostics. Hospitex offers a full range of integrated solutions aimed at streamlining diagnostic processes in cytology. The global shortage of expertise in pathology requires tools and technologies that enable diagnostic safety, efficiency and capacity building. In this area, Hospitex is recognized as the precision diagnostics player in cytology.

For more information: https://www.hospitex.com/en/

About Ikonisys

Ikonisys SA is a cell-based diagnostics company based in Paris (France), New Haven (Connecticut, USA) and Milan (Italy) specialized in the early and accurate detection of cancer. The company develops, produces and markets the proprietary Ikoniscope20 and Ikoniscope20max platforms, fully-automated solutions designed to deliver accurate and reliable detection and analysis of rare and very rare cells. Ikonisys has received FDA clearance for several automated diagnostic applications, which are also marketed in Europe under CE certification. Through its breakthrough fluorescence microscopy platform, the company continues to develop a stream of new tests, including liquid biopsy tests based on Circulating Tumor Cells (CTC).